Proteogenomic Platform for Identification of Tumor Specific Antigens

Czech version

Authors: Faktor Jakub; Hernychová Lenka; Vojtěšek Bořivoj; Hupp Theodore
Authors‘ workplace: Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2018; 31(Supplementum 2): 102-107
Category: Review
doi: https://doi.org/10.14735/amko20182S102

Overview

Background:

Although immune responses to “cancer neoantigens” have been known for decades, the first neoantigen vaccines emerged only very recently. Current developments in genomics and proteomics have enabled descriptions of tumor mutational landscapes, and the immunogenicity of corresponding neoantigens can now be predicted either in silico or in vitro. Cancer regression could be achieved via a combination of neoantigen vaccination and an appropriate immunology approach. Research in model organisms and the results of initial clinical trials of neoantigen vaccines have shown them to be effective.

Purpose:

We aim to emphasize the importance of neoantigen vaccines in personalized cancer treatment and describe their preparation. We summarize mutations leading to expression of an immunogenic antigen necessary for vaccine development. The processes leading to activation of T-cell anticancer immunity in a patient are briefly introduced. We especially focus on the identification of high confidence neoantigens by next-generation sequencing (NGS) and mass spectrometry (MS), which is key element in the process of designing neoantigen vaccines. Briefly, we describe a proteogenomic platform for confident identification of mutant peptides in biological material. We mention the possibility of neoantigen quantification in biological material using mass spectrometry such as SRM (selected reaction monitoring) and SWATH (sequential windowed acquisition of all theoretical fragment ion spectra). Successful clinical studies demonstrating the potential of neoantigen vaccination in personalized cancer treatment are summarized at the end of the paper.

Key words:

vaccination – mass spectrometry – neoplasms – organ-specific neoantigen

This work was supported by the project MEYS – NPS I – LO1413.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Accepted: 9. 7. 2018

Sources

1. Vucic EA, Thu KL, Robison K et al. Translating cancer ‘omics’ to improved outcomes. Genome Res 2012; 22 (2): 188–195. doi: 10.1101/gr.124354.111.

2. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154–158.

3. Klein G, Sjorgen HO, Klein E et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561–1572.

4. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137 (5): 1142–1162.

5. Klein J. Seeds of time: fifty years ago Peter A. Gorer discovered the H-2 complex. Immunogenetics 1986; 24 (6): 331–338.

6. Bevan MJ, Cohn M. Cytotoxic effects of antigen-and mitogen-induced T cells on various targets. J Immunol 1975; 114 (2 Pt 1): 559–565.

7. Knuth A, Danowski B, Oettgen HF et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A 1984; 81 (11): 3511–3515.

8. Wölfel T, Van Pel A, De Plaen E et al. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum-antigen with a cytolytic T cell stimulation assay. Immunogenetics 1987; 26 (3): 1780–1787.

9. Wirth TC, Kühnel F. Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front Immunol 2017; 8: 1848. doi: 10.3389/fimmu.2017.01848.

10. Jäger D, Jäger E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54 (9): 669–674.

11. Garstka MA, Fish A, Celie PH et al. The first step of peptide selection in antigen presentation by MHC class I molecules. Proc Natl Acad Sci U S A 2015; 112 (5): 1505–1510. doi: 10.1073/pnas.1416543112.

12. Dubey P, Hendrickson RC, Meredith SC et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 1997; 185 (4): 695–705.

13. Laumont CM, Perreault C. Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cell Mol Life Sci 2018; 75 (4): 607–621. doi: 10.1007/s00018-017-2628-4.

14. Worley BS, van den Broeke LT, Goletz TJ et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001; 61 (18): 6868–6875.

15. Vigneron N, Stroobant V, Chapiro J et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304 (5670): 587–590. doi: 10.1126/science.1095522.

16. Warren EH, Vigneron NJ, Gavin MA et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006; 313 (5792): 1444–1447. doi: 10.1126/science.1130660.

17. Kumar S, Banks TW, Cloutier S. SNP discovery through next-generation sequencing and its applications. Int J Plant Genomics 2012; 2012: 831460. doi: 10.1155/2012/831460.

18. Hoof I, Peters B, Sidney J et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61 (1): 1–13. doi: 10.1007/s00251-008-0341-z.

19. Harndahl M, Justesen S, Lamberth K et al. Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen 2009; 14 (2): 173–180. doi: 10.1177/1087057108329453.

20. Wisniewski JR, Ostasiewicz P, Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 2011; 10 (7): 3040–3049. doi: 10.1021/pr200019m.

21. Bouchal P, Roumeliotis T, Hrstka R et al. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 2009; 8 (1): 362–373. doi: 10.1021/pr800622b.

22. Faktor J, Bouchal P. Building mass spectrometry spectral libraries of human cancer cell lines. Klin Onkol 2016; 29 (Suppl 4): 54–58. doi: 10.14735/amko20164S54.

23. Gilar M, Olivova P, Daly AE, et al. Orthogonality of separation in two-dimensional liquid chromatography. Anal Chem 2005; 77 (19): 6426–6434. doi: 10.1021/ac050923i.

24. Finney GL, Blackler AR, Hoopmann MR et al. Label-free comparative analysis of proteomics mixtures using chromatographic alignment of high-resolution muLC-MS data. Anal Chem 2008; 80 (4): 961–971. doi: 10.1021/ac701649e.

25. Carr SA, Abbatiello SE, Ackermann BL et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014; 13 (3): 907–917. doi: 10.1074/mcp.M113.036095.

26. Gillet LC, Navarro P, Tate S et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012; 11 (6): O111.016717. doi: 10.1074/mcp.O111.016717.

27. Ott PA, Hu Z, Keskin DB et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017; 547 (7662) : 217– 221. doi: 10.1038/ nature22
991.

28. Sahin U, Derhovanessian E, Miller M et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547 (7662) : 222– 226. doi: 10.1038/ nature23003.